GSK-3i induced apoptosis in primary cells from patients with CMML or AML with SRSF2, SF3B1, or U2AF1 mutations, but not in leukemic cells with WT splicing factors or in CD34+ cells from healthy subjects (Figure 2A and Supplemental Table 1). This evidence concerns the gene SRSF2 and acute myeloid leukemia.